extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
0de2d6f707
commit
57ff8d9b6d
5 changed files with 64 additions and 1 deletions
|
|
@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
|
|||
|
||||
The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump administration Medicare deal establishes $245/month pricing (82% below list) with narrow eligibility targeting high-risk comorbid patients (~10% of Medicare beneficiaries). This fundamentally changes the cost-effectiveness calculation: the 'inflationary through 2035' conclusion assumed higher prices and broader population. With narrow targeting to patients showing strongest evidence for downstream savings (kidney disease, cardiovascular, heart failure) and 82% price reduction, the net cost impact under capitated MA plans may be neutral or positive rather than inflationary.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Medicare deal includes $50/month out-of-pocket maximum for tirzepatide starting April 2026, removing the primary financial barrier to persistence. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence more than previously understood. The $50 OOP cap may substantially improve the 15% two-year persistence rate by eliminating cost as a discontinuation factor.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Medicare deal's $50/month OOP cap explicitly addresses affordability as a persistence barrier. The deal structure (steep price reduction + low OOP cap) suggests policymakers view affordability as the primary persistence obstacle for Medicare beneficiaries, confirming that discontinuation is driven by cost rather than clinical factors.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-11-06
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: news
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
|
||||
EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare GLP-1 payment demonstration begins July 2026
|
||||
- BALANCE Model in Medicaid begins May 2026
|
||||
- BALANCE Model in Medicare Part D begins January 2027
|
||||
- Oral Wegovy launches January 2026 at $149-$299/month
|
||||
- Medicare beneficiaries pay $50/month OOP maximum for tirzepatide starting April 2026
|
||||
- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria
|
||||
|
|
|
|||
Loading…
Reference in a new issue